Franck Morschhauser
Professor of Hematology, President of LYSA
CHU de Lille / University of Lille · Lille, France
President of LYSA and LYSARC. Primary expertise in follicular lymphoma. Co-investigator on LyMa trial (led by Le Gouill). Led validation of POD24 as early indicator of poor survival in MCL (1,280 patients).
Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL).
Clinical cancer research : an official journal of the American Association for Cancer Research · Mar 2, 2026
Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA study.
Blood cancer journal · Apr 24, 2025
Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Jan 20, 2025
Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma.
Blood · Jul 18, 2024
Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial: A LYSA Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Mar 1, 2024